Loading clinical trials...
Loading clinical trials...
A Double-blinded, Randomized, Placebo-controlled, Multiple-ascending-dose Study to Assess the Safety and Pharmacokinetics of CY6463 in Participants With Stable Schizophrenia
Conditions
Interventions
CY6463
Placebo
Locations
2
United States
Collaborative Neuroscience Network
Long Beach, California, United States
Hassman Research Institute
Marlton, New Jersey, United States
Start Date
September 10, 2021
Primary Completion Date
April 18, 2022
Completion Date
April 18, 2022
Last Updated
August 13, 2024
NCT06894212
NCT04226898
NCT05240976
NCT05304767
NCT07455929
NCT06745479
Lead Sponsor
Tisento Therapeutics
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions